• Tomomi Hayase, Makiko N Mieno, Kyoko Kobayashi, Naoko Mori, Adam Jon Lebowitz, Yoko Kato, Yuya Saito, Yuki Yuza, Hirozumi Sano, Shinya Osone, Tsukasa Hori, Yuichi Shinkoda, Nobuyuki Yamamoto, Daiichiro Hasegawa, Michihiro Yano, Miho Ashiarai, Daisuke Hasegawa, Akihisa Sawada, Takuhiro Yamaguchi, Akira Morimoto, and Keitaro Fukushima.
• Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan. Electronic address: tmm.hayase@gmail.com.
• J Pain Symptom Manage. 2022 May 1; 63 (5): e495-e504.

ContextFew instruments in Japanese assess health-related quality of life in pediatric cancer patients.ObjectivesTo translate the Memorial Symptom Assessment Scale (MSAS) into Japanese pediatric and proxy versions (MSAS-J 7-12, MSAS-J 13-18, and MSAS-J-Proxy) and assess validity and reliability.MethodsPhase I comprised forward-backward translation and pilot testing in 13 children and 16 guardians. Phase II consisted of psychometric testing of the three MSAS-J versions in 162 children and 238 guardians. Internal consistency, test-retest reliability, and construct and known-group validity of the MSAS-J were assessed.ResultsCronbach's alpha coefficients for the total and subscale scores were over 0.70, excluding the psychological symptom (PSYCH) subscale score of the MSAS-J 7-12. Most MSAS-J scores significantly inversely correlated with two versions of the Pediatric Quality of Life Inventory. A strong child-guardian correlation was shown in the total and subscale scores (ICC range 0.66-0.83). Kappa estimates showed acceptable child-guardian symptom agreement. MSAS-J 7-12 and proxy differentiated patients according to clinical status.ConclusionMSAS-J is a reliable and valid instrument to assess symptoms among Japanese children with cancer.Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…